Hans Louis Jos de Winter

Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets.